MAIN PROJECT: ALPHA-01
Using advanced RNA technology, ALPHA-01 is our lead drug candidate designed to transform how we treat rare diseases related to body metabolism.
Phase IIb | 450 people | 98% purity
Phase of Growth
01
Pre-clinical
Early laboratory and animal testing to check biological activity and overall safety before the final updates.
02
Phase I Trial
First tests in a small group of healthy volunteers to check safety, dosing, and human tolerance.
03
Phase II Trial
Early studies in patient groups to show medical benefits and find the best way to use the treatment.
04
Registration
Organizing data for government approval and getting ready for the official market launch.
Milestones
Phase I Ending
MARCH 2024
Positive safety results from our first human clinical trial are now released.
JUNE 2024
Series A Investing
Raised 15M USD in funding to pay for the upcoming Phase II study.
Phase II Run
Q4 2024
Upcoming target: Scheduled beginning of patient sign-ups for trials.